ADMA Biologics, Inc. (ADMA)
- Creatore Discussione legolego
- Data di inizio
-
21-03-2023 ANNUNCIO: È da oggi disponibile il nuovo numero di “Le opportunità in Borsa”, la newsletter settimanale dedicata a consulenti finanziari ed esperti di Borsa.
Altra settimana complicata per le borse mondiali, appesantite dalle turbolenze nel settore bancario. Dopo i fallimenti delle americane SVB e Signature, le vendite hanno investito Credit Suisse, il cui principale azionista ha annunciato l’intenzione di non iniettare ulteriore capitale nell’istituto. Dapprima, la banca centrale svizzera ha fornito un prestito da 50 miliardi di franchi e poi il governo ha orchestrato una cessione alla connazionale UBS per 3 miliardi di franchi. Inoltre, le principali banche centrali hanno annunciato un’azione coordinata per aumentare la liquidità in dollari, alimentando i dubbi sullo stato di salute dell’intero sistema bancario.
Per continuare a leggere visita il link
ADMA Biologics, Inc. (ADMA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
3.7400+0.9000 (+31.69%)
At close: July 30 4:00PM EDT
4.1500 +0.41 (10.96%)
Before hours: 4:09AM EDT
ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Quote Lookup
3.7400+0.9000 (+31.69%)
At close: July 30 4:00PM EDT
4.1500 +0.41 (10.96%)
Before hours: 4:09AM EDT
ADMA Biologics to Report Business Highlights and Second Quarter 2020 Financial Results on August 5, 2020
Biotechfun
Nuovo Utente
- Registrato
- 30/5/12
- Messaggi
- 3.112
- Punti reazioni
- 56
plasma stocks on fire....
Dr Strangelove
Nuovo Utente
- Registrato
- 17/8/17
- Messaggi
- 185
- Punti reazioni
- 20
Biotechfun
Nuovo Utente
- Registrato
- 30/5/12
- Messaggi
- 3.112
- Punti reazioni
- 56
Ne conosci altre meritevoli di attenzioni oggi?
domani earnings 
aspetto solo notizie positive dall'ultima trimestrale.
Intanto hanno aperto altri centri di raccolta plasma e chissà che non dicano quante sacche hanno in deposito
Tornano buone per il covid-19 ovviamente, e tra l'altro sono tutte donazioni
aspetto solo notizie positive dall'ultima trimestrale.
Intanto hanno aperto altri centri di raccolta plasma e chissà che non dicano quante sacche hanno in deposito
Tornano buone per il covid-19 ovviamente, e tra l'altro sono tutte donazioni
Adma Biologics (ADMA) Reports Q2 Loss, Lags Revenue Estimates
Adma Biologics (ADMA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.25 per share a year ago.
i conti deludono le aspettative, ma quello che conta per me è qui tra le righe:
While the second quarter 2020 revenues were approximately 19% higher than second quarter 2019 revenues, ADMA, and certain of its third-party vendors, experienced impacts from the global COVID-19 pandemic which resulted in unforeseen supply chain disruptions. These COVID-19 disruptions were primarily related to delays with final product Current Good Manufacturing Practice (“cGMP”) release testing by third-party vendors. This means that a few of our production batches were finished on schedule but we were unable to submit for U.S. Food and Drug Administration (“FDA”) lot release authorization due to delayed test results.
“These delays were mainly experienced during the latter part of the second quarter and have since been resolved during July. In response to these delays, and in partnership with the FDA, we added additional release testing laboratories to our approved consortium and believe we have completely resolved the issue and do not anticipate additional testing or batch release delays going forward.
“Market demand for our immunoglobulin product portfolio remains strong and we anticipate considerable revenue growth for the second half of the year and are excited for the anticipated production volume increases from our capacity expansion efforts in 2021 and beyond. We also believe we remain on track to achieve our stated goal of generating $250 million or more in annual revenues within the next three to five calendar years.
“In accordance with our stated corporate objectives, during the quarter we completed construction of a new plasma collection center, initiated donor collections and submitted a Biologics License Application (“BLA”) to the FDA, with an approval decision expected in mid-2021. We also installed and qualified a new aseptic fill-finish machine at our Boca Raton facility, and manufactured conformance batches of BIVIGAM® at an increased scale that will ultimately allow us to manufacture at twice the volume as the process that is in place today. And finally, we joined the CoVIg-19 Plasma Alliance and began collection of plasma from COVID-19 convalesced patients. We are proud of these important achievements and milestones and believe we have set the stage to now be in a position to ensure the U.S. market has a continuous supply of BIVIGAM®, ASCENIV™ and NABI-HB®. We are on target for positioning our operations to capitalize on the continued forecasted growth of the plasma products industry. Our production throughput and finished product supply remains on track to begin realizing the benefits from these initiatives as early as mid-2021,” concluded Mr. Grossman.
Adma Biologics (ADMA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.25 per share a year ago.
i conti deludono le aspettative, ma quello che conta per me è qui tra le righe:
While the second quarter 2020 revenues were approximately 19% higher than second quarter 2019 revenues, ADMA, and certain of its third-party vendors, experienced impacts from the global COVID-19 pandemic which resulted in unforeseen supply chain disruptions. These COVID-19 disruptions were primarily related to delays with final product Current Good Manufacturing Practice (“cGMP”) release testing by third-party vendors. This means that a few of our production batches were finished on schedule but we were unable to submit for U.S. Food and Drug Administration (“FDA”) lot release authorization due to delayed test results.
“These delays were mainly experienced during the latter part of the second quarter and have since been resolved during July. In response to these delays, and in partnership with the FDA, we added additional release testing laboratories to our approved consortium and believe we have completely resolved the issue and do not anticipate additional testing or batch release delays going forward.
“Market demand for our immunoglobulin product portfolio remains strong and we anticipate considerable revenue growth for the second half of the year and are excited for the anticipated production volume increases from our capacity expansion efforts in 2021 and beyond. We also believe we remain on track to achieve our stated goal of generating $250 million or more in annual revenues within the next three to five calendar years.
“In accordance with our stated corporate objectives, during the quarter we completed construction of a new plasma collection center, initiated donor collections and submitted a Biologics License Application (“BLA”) to the FDA, with an approval decision expected in mid-2021. We also installed and qualified a new aseptic fill-finish machine at our Boca Raton facility, and manufactured conformance batches of BIVIGAM® at an increased scale that will ultimately allow us to manufacture at twice the volume as the process that is in place today. And finally, we joined the CoVIg-19 Plasma Alliance and began collection of plasma from COVID-19 convalesced patients. We are proud of these important achievements and milestones and believe we have set the stage to now be in a position to ensure the U.S. market has a continuous supply of BIVIGAM®, ASCENIV™ and NABI-HB®. We are on target for positioning our operations to capitalize on the continued forecasted growth of the plasma products industry. Our production throughput and finished product supply remains on track to begin realizing the benefits from these initiatives as early as mid-2021,” concluded Mr. Grossman.
Dr Strangelove
Nuovo Utente
- Registrato
- 17/8/17
- Messaggi
- 185
- Punti reazioni
- 20
bella bastonata
piombato preciso al mio pmc ..prese altre a 2,92
piombato preciso al mio pmc ..prese altre a 2,92chavallo67
Nuovo Utente
- Registrato
- 16/3/05
- Messaggi
- 12.572
- Punti reazioni
- 284
ADMA Pre-market 4.31 +1.79 (71.03%)
Grifols, Takeda e Csl avvantaggiate da ok Fda all'uso del plasma nella cura del Covid-19 - MilanoFinanza.it
Grifols, Takeda e Csl avvantaggiate da ok Fda all'uso del plasma nella cura del Covid-19 - MilanoFinanza.it
magolibero
..ma se la sà gira..
- Registrato
- 9/3/00
- Messaggi
- 3.295
- Punti reazioni
- 190
50 % italica nell'affaire : KEDRION
100 % israeliana nella quotazione : KAMADA (KMDA)
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment
100 % israeliana nella quotazione : KAMADA (KMDA)
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment
Ultima modifica:
ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma
il titolo per ora ha deluso le mie aspettative, sottolineo per ora.
Purtroppo notizie contrastanti circa l'utilizzo o meno del plasma come trattamento per il covid non hanno permesso benefici in termini di quotazione...
...today announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma. ImmunoRank™ was developed in collaboration with Leinco Technologies, Inc. (“Leinco”). ImmunoRank is intended for use as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, and specifically for the detection of circulating SARS-CoV-2 neutralizing antibodies in human plasma of all immune globulin classes.
ImmunoRank is designed to test up to 90 samples per test kit with 99.8% specificity. The assay procedure takes approximately 80 minutes. An Emergency Use Authorization (EUA) submission is currently being prepared for review and potential approval by the U.S. Food and Drug Administration...
la seguo sempre---
il titolo per ora ha deluso le mie aspettative, sottolineo per ora.
Purtroppo notizie contrastanti circa l'utilizzo o meno del plasma come trattamento per il covid non hanno permesso benefici in termini di quotazione...
...today announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma. ImmunoRank™ was developed in collaboration with Leinco Technologies, Inc. (“Leinco”). ImmunoRank is intended for use as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, and specifically for the detection of circulating SARS-CoV-2 neutralizing antibodies in human plasma of all immune globulin classes.
ImmunoRank is designed to test up to 90 samples per test kit with 99.8% specificity. The assay procedure takes approximately 80 minutes. An Emergency Use Authorization (EUA) submission is currently being prepared for review and potential approval by the U.S. Food and Drug Administration...
la seguo sempre---
ADMA Biologics Opens Newest ADMA BioCenters Plasma Collection Facility in Maryville, TN
interessante qui :
....The FDA regulatory process for obtaining approval for this plasma collection center includes a site inspection and an approximately 12-month BLA review period. As such, ADMA expects to receive an approval decision for this third plasma facility in the fourth quarter of 2021. In the meantime, ADMA is permitted to collect plasma donations at this site, and once FDA approved, it can use the plasma collected for production of its FDA approved immunoglobulin products....
interessante qui :
....The FDA regulatory process for obtaining approval for this plasma collection center includes a site inspection and an approximately 12-month BLA review period. As such, ADMA expects to receive an approval decision for this third plasma facility in the fourth quarter of 2021. In the meantime, ADMA is permitted to collect plasma donations at this site, and once FDA approved, it can use the plasma collected for production of its FDA approved immunoglobulin products....
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 9.077
- Punti reazioni
- 434
sono un pò dubbioso, si parla di fine 2021 per l'approvazione , se il vaccino funziona pensi possa ancora servire tutto questo plasma ?
sono due piani differenti IMO: l'approccio dei vaccini è quello di EVITARE di essere contagiati/contagiosi, nel più breve tempo possibile, senza "troppi fronzoli". L'altro piano è quello del TRATTAMENTO in caso di infezione. E Sicuramente non è con il vaccino che verrà risolta la questione, sia perchè non vi è obbligatorietà, sia perchè i tempi saranno lunghi per vaccinare una bella fetta di popolazione.
Un 40enne sano, non penso abbia idea di farsi vaccinare per il covid...e se sfiga vuole che se lo prende e va in terapia intensiva...ecco che c'è un trattamento.
Per ora in Italia lo stanno usando in Veneto, e sperimentando al niguarda...
Inoltre circa la "durata delle copertura" del vaccino si sa molto poco, e da quel poco si desume che comunque sarebbe una vaccinazione " a scadenza" di tot mesi...dopo di che devi rivaccinarti (un po' come la classica influenza stagionale anno dopo anno).
Comunque, nessuno potrà sapere il futuro...scrivo solo quello che penso, ma sicuramente ci sono altre 1000 logiche diverse, e "pro" e "contro" in qualsiasi modo di vedere le cose.
ADMA intanto colleziona plasma iperimmune, ed è sin da ora autorizzata ad utilizzarlo in tutti prodotti già approvati "...can use the plasma collected for production of its FDA approved immunoglobulin products", magari torna utile...magari no...chissà
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 9.077
- Punti reazioni
- 434
bene grazie delle info, io sono entrato, la situazione grafica è interessante anche se ha gli oscillatori un pò tirati, ieri ha fatto nuovi massimi del mese
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook
2.35+0.29 (+14.0777%)
As of 10:46AM EST. Market open.
2.35+0.29 (+14.0777%)
As of 10:46AM EST. Market open.